Global Markets Direct’s pharmaceuticals report, “Inviragen, Inc. - Product Pipeline Review - 2013” provides data on the Inviragen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Inviragen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Inviragen, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Inviragen, Inc. - Brief Inviragen, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Inviragen, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Inviragen, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Inviragen, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Inviragen, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Inviragen, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Inviragen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Inviragen, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Inviragen, Inc. and identify potential opportunities in those areas.
Table Of Contents
Inviragen, Inc. - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Inviragen, Inc. Snapshot 4 Inviragen, Inc. Overview 4 Key Information 4 Key Facts 4 Inviragen, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Inviragen, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Inviragen, Inc. - Pipeline Products Glance 9 Inviragen, Inc. Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Inviragen, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Inviragen, Inc. - Drug Profiles 12 Avian Influenza Vaccine 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 Chikungunya Vaccine 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 DENVax 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 HPV Vaccine 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 INV-21 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 Japanese Encephalitis Vaccine 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 Plague Vaccine 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 Inviragen, Inc. - Pipeline Analysis 19 Inviragen, Inc. - Pipeline Products by Therapeutic Class 19 Inviragen, Inc. - Pipeline Products by Route of Administration 20 Inviragen, Inc. - Recent Pipeline Updates 21 Inviragen, Inc. - Locations And Subsidiaries 24 Head Office 24 Other Locations and Subsidiaries 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables
Inviragen, Inc., Key Information 4 Inviragen, Inc., Key Facts 4 Inviragen, Inc. - Pipeline by Indication, 2013 6 Inviragen, Inc. - Pipeline by Stage of Development, 2013 7 Inviragen, Inc. - Monotherapy Products in Pipeline, 2013 8 Inviragen, Inc. - Phase II, 2013 9 Inviragen, Inc. - Phase I, 2013 10 Inviragen, Inc. - Preclinical, 2013 11 Inviragen, Inc. - Pipeline By Therapeutic Class, 2013 19 Inviragen, Inc. - Pipeline By Route of Administration, 2013 20 Inviragen, Inc. - Recent Pipeline Updates, 2013 21 Inviragen, Inc., Other Locations 24
List of Figures
Inviragen, Inc. - Pipeline by Indication, 2013 6 Inviragen, Inc. - Pipeline by Stage of Development, 2013 7 Inviragen, Inc. - Monotherapy Products in Pipeline, 2013 8 Inviragen, Inc. - Pipeline By Therapeutic Class, 2013 19 Inviragen, Inc. - Pipeline By Route of Administration, 2013 20